The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | The ANCHOR and LIGHTHOUSE trials: melfulfen combination treatment in RRMM
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, discusses the ANCHOR trial (NCT03481556), which investigated melphalan flufenamide (melflufen) with dexamethasone plus either bortezomib or daratumumab in relapsed/refractory multiple myeloma (RRMM). The trial showed good responses and tolerability in both arms. These positive results led to the Phase III LIGHTHOUSE study (NCT04649060), which found a significant benefit of combining melflufen, dexamethasone, and daratumumab compared to daratumumab alone. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria/Consultancy: Janssen, BMS, Sanofi, GSK, Oncopeptides, Amgen, Takeda, Secura-Bio, MSD, Mundipharma-EDO.
